AN2 Therapeutics (ANTX) Current Leases (2022 - 2023)
AN2 Therapeutics (ANTX) posted quarterly Current Leases of $13000.0 for Q2 2023, little changed year-over-year from $13000.0 in Q2 2022, and down 61.76% quarter-over-quarter from $34000.0 in Q1 2023.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Current Leases (2022 - 2023) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Current Leases for 2 consecutive years, with $13000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Current Leases changed 0.0% year-over-year to $13000.0; the TTM figure through Jun 2023 stood at $13000.0 (changed 0.0% YoY), while the FY2022 annual figure was $53000.0, changed N/A from the prior year.
- Current Leases declined to $13000.0 in Q2 2023 per ANTX's latest filing, from $34000.0 in the prior quarter.
- Across five years, Current Leases topped out at $73000.0 in Q3 2022 and bottomed at $13000.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 13,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Sep 30, 2022 | 73,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | 32,000.00 |